Compare AbCellera Biologics Inc (ABCL) vs iShares Semiconductor ETF (SOXX) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

SOXX, the iShares Semiconductor ETF, trades at $581.51, up 2.68% in the last 24 hours, with a neutral technical signal but bullish moving averages. The ETF has surged 93.3% year-to-date, driven by AI chip demand, yet faces recent volatility as hedge funds reduced exposure. Key support sits at $575, with resistance at $593. Financial ratios are not applicable for this ETF structure, which holds 30 U.S. semiconductor stocks.

Outlook remains cautiously optimistic given AI-driven growth, but risks include sector rotation, valuation concerns after sharp gains, and macroeconomic pressures. JPMorgan advises buying the dip, while Morgan Stanley notes potential pivot to hyperscalers. Investors should weigh strong thematic tailwinds against near-term volatility and high beta exposure.